State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210093, China.
Molecules. 2014 Jun 3;19(6):7269-86. doi: 10.3390/molecules19067269.
A series of caffeic acid amides D1-D17 bearing 2,3,4,5-tetrahydrobenzo-[b][1,4]dioxocine units has been synthesized and their biological activities evaluated for potential antiproliferative and EGFR inhibitory activity. Of all the compounds studied, compound D9 showed the most potent inhibitory activity (IC50=0.79 μM for HepG2 and IC50=0.36 μM for EGFR). The structures of compounds were confirmed by 1H-NMR, ESI-MS and elemental analysis. Among all, the structure of compound D9 ((E)-N-(4-ethoxyphenyl)-3-(2,3,4,5-tetrahydrobenzo[b][1,4]dioxocin-8-yl)acrylamide) was also determined by single-crystal X-ray diffraction analysis. Compound D9 was found to be a potential antitumor agent according to biological activity, molecular docking, apoptosis assay and inhibition of HepG2.
已经合成了一系列含有 2,3,4,5-四氢苯并[b][1,4]二恶烷单元的咖啡酸酰胺 D1-D17，并对其进行了评估，以研究其对潜在的抗增殖和 EGFR 抑制活性的生物活性。在所研究的所有化合物中，化合物 D9 表现出最强的抑制活性（对 HepG2 的 IC50=0.79 μM，对 EGFR 的 IC50=0.36 μM）。化合物的结构通过 1H-NMR、ESI-MS 和元素分析得到证实。在所有这些化合物中，化合物 D9（（E）-N-（4-乙氧基苯基）-3-（2,3,4,5-四氢苯并[b][1,4]二恶烷-8-基）丙烯酰胺）的结构也通过单晶 X 射线衍射分析确定。根据生物活性、分子对接、细胞凋亡测定和对 HepG2 的抑制作用，发现化合物 D9 是一种潜在的抗肿瘤药物。
